Search results for "OUTCOME"

showing 10 items of 5148 documents

Real-world evidence from a European cohort study of patients with treatment resistant depression : Baseline patient characteristics

2021

Journal of affective disorders 283, 115-122 (2021). doi:10.1016/j.jad.2020.11.124

AdultMaleDisease burden; Health-related quality of life; Major depressive disorder; Observational study; Patient-reported outcomes; Socio-economic status; Adult; Cohort Studies; Europe; Female; Humans; Male; Middle Aged; Quality of Life; Depressive Disorder Major; Depressive Disorder Treatment-Resistantmedicine.medical_specialtyHealth-related quality of lifeSocio-economic statusMajor depressive disorderCohort Studies03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineQuality of lifeObservational studyInternal medicinemedicineHumansMedical historyDepression (differential diagnoses)Disease burdenDepressive DisorderDepressive Disorder MajorPatient-reported outcomesDisease burden Health-related quality of life Major depressive disorder Observational study Patient-reported outcomes Socio-economic statusbusiness.industryTreatment-ResistantMajorDisease burdenMiddle Agedmedicine.disease030227 psychiatry3. Good healthEuropePsychiatry and Mental healthClinical PsychologyPresenteeismQuality of LifeMajor depressive disorderFemalebusinessTreatment-resistant depression030217 neurology & neurosurgeryCohort study
researchProduct

Recovery from depressive symptoms, state anxiety and post-traumatic stress disorder in women exposed to physical and psychological, but not to psycho…

2010

Abstract Background It is well established that intimate male partner violence (IPV) has a high impact on women's mental health. It is necessary to further investigate this impact longitudinally to assess the factors that contribute to its recovery or deterioration. The objective of this study was to assess the course of depressive, anxiety and post-traumatic stress disorder (PTSD) symptoms and suicidal behavior over a three-year follow-up in female victims of IPV. Methods Women (n = 91) who participated in our previous cross-sectional study, and who had been either physically/psychologically (n = 33) or psychologically abused (n = 23) by their male partners, were evaluated three years late…

AdultMaleDomestic ViolenceLongitudinal studymedicine.medical_specialtylcsh:RC435-571Health StatuseducationPoison controlComorbiditySocial EnvironmentSuicide preventionbehavioral disciplines and activitiesLife Change EventsStress Disorders Post-TraumaticSocial supportSex FactorsSurveys and Questionnaireslcsh:PsychiatryOutcome Assessment Health Caremental disordersmedicineHumansLongitudinal StudiesPsychiatryDepressionTraumatic stressSocial Supportsocial sciencesMiddle AgedAnxiety DisordersMental healthPsychiatry and Mental healthMental HealthSpouse AbuseWomen's HealthAnxietyDomestic violencepopulation characteristicsFemalemedicine.symptomPsychologyFollow-Up StudiesResearch ArticleClinical psychology
researchProduct

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)

2021

In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile.This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice.The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes included the rates of seizure-freedom, s…

AdultMaleDrug Resistant EpilepsyLevetiracetamEpilepsy CNS therapyCorrectionMiddle AgedSettore MED/26PyrrolidinonesPsychiatry and Mental healthTreatment OutcomeItalyChemotherapy AdjuvantHumansPharmacology (medical)AnticonvulsantsFemaleNeurology (clinical)Epilepsies PartialRetrospective Studies
researchProduct

Improved drug-use patterns at 6 months post-discharge from inpatient substance use disorder treatment: Results from compulsorily and voluntarily admi…

2016

Background Treatment services to patients with substance use disorders (SUDs), including those mandated to treatment, needs to be evaluated and evidence based. The Norwegian Municipal Health Care Act calls for mandated treatment for persons with “severe and life-threatening substance use disorder” if these individuals are not otherwise willing to be voluntarily treated and consequently risk their lives over drug use. This study aims to examine substance use–related outcomes at 6 months following inpatient treatment and to analyse factors associated with improved outcomes and abstinence. Method This prospective study followed 202 hospitalized patients with SUD who were admitted voluntarily (…

AdultMaleDrugmedicine.medical_specialtyEvidence-based practiceSubstance-Related DisordersCompulsory treatmentmedia_common.quotation_subject030508 substance abuseMandatory ProgramsSubstance use disorderMedication Adherence03 medical and health sciences0302 clinical medicineInternal medicineHealth caremedicineHumansProspective Studies030212 general & internal medicinePsychiatryAmphetamineProspective cohort studymedia_commonInpatientsNorwaybusiness.industryPublic healthHealth PolicyAbstinencemedicine.diseasePatient DischargeHospitalizationSubstance abuseTreatment OutcomeRegression AnalysisFemale0305 other medical sciencebusinessResearch Articlemedicine.drug
researchProduct

A randomized trial assessing the effectiveness of different concentrations of isotretinoin in the management of lichen planus

2004

The aim of our 10-year study was to test the effectiveness of topical therapy based on 0. 18% isotretinoin, comparing it with that most frequently used, i.e. at 0.05% concentration. Seventy patients with an established diagnosis of oral lichen planus were involved in the study. The patients were randomly divided into two groups, and the drug was administered topically at 0.05% and 0. 18% concentrations. The drug at the higher concentration, according to the same protocol, was administered to the patients who did not benefit from the therapy at the lower concentration. None of the cases of reticular lichen planus showed clinical or histological improvement. In contrast, the atrophic-erosive …

AdultMaleDrugmedicine.medical_specialtyHot TemperatureRandomizationAdministration Topicalmedicine.medical_treatmentmedia_common.quotation_subjectSensationPainoral lichen planus isotretinoinlaw.inventionRandomized controlled trialRecurrencelawOral and maxillofacial pathologyHumansMedicineIsotretinoinOral UlcerIsotretinoinAgedmedia_commonChemotherapybusiness.industrySmokingMiddle Agedmedicine.diseaseDermatologyClinical trialstomatognathic diseasesTreatment OutcomeOtorhinolaryngologyFemaleSurgeryOral lichen planusDermatologic AgentsOral SurgerybusinessFollow-Up StudiesLichen Planus Oralmedicine.drug
researchProduct

Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes

2013

The safety of BVS implantation in patients with a high risk for early thrombotic complications has not been studied. We report on the outcomes of patients with acute coronary syndromes (ACS) treated with bioresorbable, everolimus-eluting, vascular scaffolds (BVS).150 consecutive patients with ACS (194 lesions) treated with BVS between May 2012 and July 2013 were compared with a control group composed of 103 consecutive patients (129 lesions) who underwent everolimus drug-eluting stent (DES) implantation in the same time period. The incidence of major adverse cardiac events (MACE: death, non-fatal myocardial infarction, or reintervention) before discharge, at one month and six months was eva…

AdultMaleDrugmedicine.medical_specialtyTime Factorsmedia_common.quotation_subjectmedicine.medical_treatmentmedicineHumansIn patientEverolimusMyocardial infarctionAcute Coronary SyndromeAgedmedia_commonAged 80 and overSirolimusEverolimusbusiness.industryIncidence (epidemiology)StentCardiovascular AgentsDrug-Eluting StentsMiddle Agedmedicine.diseaseThrombosisSurgeryTreatment OutcomeFemaleCardiology and Cardiovascular MedicinebusinessMacemedicine.drugEuroIntervention
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Pregnancy Outcome in Maternal Crigler-Najjar Syndrome Type II: A Case Report and Systematic Review of the Literature

2008

<i>Objective:</i> To report a case of maternal Crigler-Najjar syndrome (CNS) type II in pregnancy, systematically review the literature for similar case reports, and to evaluate whether pregnancy is safe in patients with the disease. Data sources included the PubMed and uptodate databases. <i>Results:</i> A 37-year-old mother with CNS type II was treated with phenobarbital during her pregnancy and her bilirubin levels were monitored. Her newborn had mild direct hyperbilirubinemia, did not require any treatment and his postnatal follow-up showed normal growth and development as well as normal hearing. <i>Conclusion:</i> CNS type II is rare, and only a few …

AdultMaleEmbryologyPediatricsmedicine.medical_specialtyBilirubinCrigler–Najjar syndromeDiseasechemistry.chemical_compoundPregnancymedicineHumansRadiology Nuclear Medicine and imagingNeonatologyHearing DisordersKernicterusCrigler-Najjar SyndromePregnancyFetusbusiness.industryInfant NewbornPregnancy OutcomeInfantObstetrics and GynecologyBilirubinGeneral Medicinemedicine.diseaseSurgeryPregnancy ComplicationschemistryPhenobarbitalPediatrics Perinatology and Child HealthGestationFemalePhenobarbitalbusinessmedicine.drugFetal Diagnosis and Therapy
researchProduct

Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure

2012

BACKGROUND & AIMS: Fractionated plasma separation and adsorption (FPSA) is an extracorporeal procedure that supports liver function by removing endogenous toxins that cause complications from acute-on-chronic liver failure (AOCLF). We performed a randomized trial to investigate survival of patients with AOCLF treated with FPSA. METHODS: Patients with AOCLF were randomly assigned to groups given a combination of FPSA and standard medical therapy (SMT) (FPSA group, n = 77) or only SMT (SMT group, n = 68). The Prometheus liver support system was used to provide 8 to 11 rounds of FPSA (minimum of 4 hours each) for 3 weeks. Primary end points were survival probabilities at days 28 and 90, irresp…

AdultMaleExtracorporeal Circulationmedicine.medical_specialtyTime FactorsCirrhosismedicine.medical_treatmentMedizinKaplan-Meier EstimateLiver transplantationRisk AssessmentGastroenterologyEnd Stage Liver DiseaseLIVER DISEASELiver diseaseSpontaneous bacterial peritonitisHepatorenal syndromeRisk FactorsInternal medicinemedicineHumansProspective StudiesDialysisProportional Hazards ModelsHepatologybusiness.industryMORTALITYGastroenterologyBilirubinTREATMENTLiver Failure AcuteMiddle Agedmedicine.diseaseEXTRACORPOREAL LIVER SUPPORTSurgeryEuropeTreatment OutcomeFemaleSorption DetoxificationSOFA scoreLiver functionORGAN FAILUREbusinessBiomarkers
researchProduct

Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year r…

2009

BackgroundEmpirical evidence of the efficacy and effectiveness of psychosocial family intervention and of the specificity of its effects on the course of schizophrenia is limited. The aim was to study the efficacy and effectiveness of psychosocial family intervention with regard to clinical and social functioning and family burden after controlling for compliance and several prognostic factors.MethodA 2-year randomized controlled trial with blind assessments. Fifty patients with DSM-IV schizophrenia and persistent positive symptoms and/or previous clinical relapse were allocated to psychosocial family intervention, individual counselling and standard treatment versus individual counselling …

AdultMaleFamily therapymedicine.medical_specialtylaw.inventionYoung AdultCost of IllnessRandomized controlled triallawIntervention (counseling)Secondary PreventionmedicineHumansSchizophreniform disorderPsychiatryApplied PsychologyPsychiatric Status Rating ScalesStandard treatmentSocial environmentmedicine.diseaseCombined Modality TherapyPsychotherapyPsychiatry and Mental healthTreatment OutcomeCaregiversPsychotic DisordersSpainSchizophreniaSchizophreniaPatient ComplianceFamily TherapyFemaleSchizophrenic PsychologyPsychologySocial AdjustmentPsychosocialAntipsychotic AgentsPsychological Medicine
researchProduct